Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

----------------

Cash provided by financing

activities - 12,068,172 96,253,751

-------------------------------------------------------------------------

Net increase in cash and cash

equivalents during the period 611,610 7,833,768 7,326,706

Cash and cash equivalents,

beginning of the period 6,715,096 3,491,511 -

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Cash and cash equivalents,

end of the period 7,326,706 11,325,279 7,326,706

-------------------------------------------------------------------------

-------------------------------------------------------------------------

See accompanying notes

Oncolytics Biotech Inc.

NOTES TO FINANCIAL STATEMENTS

March 31, 2008 (unaudited)

1. INCORPORATION AND NATURE OF OPERATIONS

Oncolytics Biotech Inc. (the "Company" or "Oncolytics") was incorporated

on April 2, 1998 under the Business Corporations Act (Alberta) as 779738

Alberta Ltd. On April 8, 1998, the Company changed its name to Oncolytics

Biotech Inc.

The Company is a development stage biopharmaceutical company that focuses

on the discovery and development of pharmaceutical products for the

treatment of cancers that have not been successfully treated with

conventional therapeutics. The product being developed by the Company may

represent a novel treatment for Ras mediated cancers which can be used as

an alternative to existing cytotoxic or cytostatic therapies, as an

adjuvant therapy to conventional chemotherapy, radiation therapy, or

surgical resections, or to treat certain cellular proliferative disorders

for which no current thera
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 19, 2014 Naurex Inc., a biopharmaceutical ... for diseases of the central nervous system, today announced ... executive officer, will present at the 33 rd ... take place at 3:00 p.m. PST on Tuesday, January ... San Francisco, Calif. ...
(Date:12/19/2014)... -- Decision Resources Group finds that the Latin American ... compound annual growth rate through 2023. This is primarily ... increasing adoption of dental implants. Growing aesthetic consciousness in ... demand for dental biomaterials because they can improve the ... Other key findings from Decision Resources Group,s coverage ...
(Date:12/19/2014)... Today, TiFiber, Inc. announced ... and future company headquarters in Fort Smith, Arkansas ... that safely and effectively control dangerous microorganisms. Fort ... historic, strong support for manufacturing, but also due ... technology-based companies such as TiFiber. , In ...
(Date:12/19/2014)... Reports from CDC show approximately 117 ... or more chronic health conditions - including cardiovascular disease, ... of these diseases, but may not eliminate the severe ... implanted nerve stimulation devices today offer relief, they require ... induce side effects. , To eliminate the need ...
Breaking Biology Technology:Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2
... French . , A new nanotech catalyst developed by McGill ... offers industry an opportunity to reduce the use of ... to facilitate and drive chemical reactions. Although chemists have ... of traditional chemical catalysts and do attempt to reuse ...
... BERWYN, Pa. , Feb. 16 Encorium Group, ... research organization (CRO) conducting studies in over 30 countries for ... announced that it had filed a Certificate of Amendment to ... the State of Delaware to affect a reverse ...
... , , SAN FRANCISCO , Feb. 16 ... sector will showcase innovative new initiatives at Informex this week, ... world-class solutions to the global chemicals industry. , At Informex ... unprecedented partnership between seven leading universities, the private sector and ...
Cached Biology Technology:Encorium Group, Inc. Announces One-for-Eight Reverse Stock Split 2Encorium Group, Inc. Announces One-for-Eight Reverse Stock Split 3Encorium Group, Inc. Announces One-for-Eight Reverse Stock Split 4Encorium Group, Inc. Announces One-for-Eight Reverse Stock Split 5Encorium Group, Inc. Announces One-for-Eight Reverse Stock Split 6Scotland Launches Chemicals Industry Partnerships To Propel $13 Billion Sector 2Scotland Launches Chemicals Industry Partnerships To Propel $13 Billion Sector 3Scotland Launches Chemicals Industry Partnerships To Propel $13 Billion Sector 4
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint ... http://photos.prnewswire.com/prnh/20130307/600769 ... than the iPhone 5S, Samsung introduces for the ... The Galaxy S5 home button presents ...
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel ... at international borders. Over the past decade, ePassports, ... veteran travelers to self process through border control ... at an increasing number of airports, seaports, and ... According to Maxine Most , Principal at ...
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the ... a new series of digital telemetry implants to ... M series, part of the PhysioTel™ Digital platform, ... possible physiologic data when incorporating functional endpoints into ... to toxicology studies has evolved from short ECG ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... of Alabama at Birmingham (UAB) departments of Pathology, Microbiology and ... Heart, Lung, and Blood Institute (NHLBI) to study so-called red ... changes in red blood cells that have been stored for ... focus on the mechanisms by which red blood cell storage ...
... August of 2008 Jacob Schaefer, PhD, on vacation in San Diego, ... it happened, the newspaper was running a series on the wildfires ... more frequent they now occur every few years instead of ... The more intense fire cycle is fueled by cheatgrass (Bromus tectorum), ...
... BOSTON, Mass. (June 20, 2010) By emulating nature,s ... Biologically Inspired Engineering, Harvard Medical School and Dana-Farber Cancer ... and can be programmed to move and change shape ... nanodevices are highly suitable for medical applications because DNA ...
Cached Biology News:NHLBI grants $1.47 million to study red blood cell transfusion storage times and bioactivity 2In elevated carbon dioxide, soybeans stumble but cheatgrass keeps on truckin' 2In elevated carbon dioxide, soybeans stumble but cheatgrass keeps on truckin' 3In elevated carbon dioxide, soybeans stumble but cheatgrass keeps on truckin' 4In elevated carbon dioxide, soybeans stumble but cheatgrass keeps on truckin' 5Researchers create self-assembling nanodevices that move and change shape on demand 2
... of gene expression) technology allows ... profiles generated by SAGE are ... transcripts making it possible to ... Kit is designed to make ...
Sheep Serum US Origin...
... For the ultimate in utility and ... to meet the needs of the researcher. ... interior dimensions or as sheet material that ... enclosures. These isolators are autoclavable and non-cytotoxic ...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
Biology Products: